news

 

Indian law firm Saraf & Partners has added Ramya Suresh from AZB & Partners, the firm’s second M&A partner hire in Mumbai in a fortnight following the addition of Dhruv Chatterjee from Trilegal at the end of September.            

Suresh is a transactions attorney with experience guiding cross-border deals and private equity ventures across sectors, particularly infrastructure, healthcare, consumer products, energy, and financial services.

She was recently on the AZB team that successfully represented the promoters of Reliance Industries Limited in a dispute with the securities regulator, Securities and Exchange Board of India, over allegations of non-compliance with certain regulations.

In her time at Trilegal, prior to AZB, she advised institutional investor Naspers on its lead role in a $540 million funding round into edtech company Byju's.

Saraf had also added tax partner Amit Gupta in Delhi and merged with real estate boutique SRGR earlier this year.

The firm has a total of 35 partners across offices in Delhi, Mumbai and Bengaluru.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, WFW act on $185 mln Adani Ports acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas advised its longstanding client Adani on Adani Ports and Special Economic Zone’s acquisition of 80 percent stake in Astro Offshore, an offshore support vessel operator. Watson Farley & Williams advised the selling shareholders of Astro Offshore.

Anagram adds M&A and PE partner from IndusLaw

by Nimitt Dixit |

M&A-focused Anagram Partners has become the latest to turn to IndusLaw to expand its offerings with the addition of M&A and private equity-focused partner Faraz Khan in Mumbai.

Trilegal, Latham, Quillon act on Platinum Equity’s India PE debut

by Nimitt Dixit |

Trilegal and Latham & Watkins have advised U.S.-based buyout fund Platinum Equity on its debut private equity deal in India, in the form of the acquisition of a majority stake in Inventia Healthcare, a Mumbai-based pharmaceutical company, at a valuation of $300 million.